On January 1, 2020, the revised Swiss integrity, transparency and discounts (ITD) regime in the therapeutic products sector came into force.

On March 10 2024, Switzerland – together with fellow European Free Trade Association members Liechtenstein, Norway and Iceland – signed the ‘Trade and Economic Partnership Agreement' with India.

The import of medicinal products authorized abroad into Switzerland can have a variety of motives, the main ones being to ensure cross-border medical supplies, offset excess stocks in foreign storage facilities.

Nowadays, there is almost no active medical device without some interaction with software.

These regulations include new categories as well as additional provisions for genetic testing.

On 18 March 2016, the Swiss Parliament adopted the revised Therapeutic Products Act (revTPA).

Fiscal import involves the purchase or procurement "on paper" of medicines that have not left the territory of the European Union from an entity based outside the EU.

In its judgment of 22 January 2026 (C-9459/2025), the Swiss Federal Administrative Court (FAC) clarified a fundamental procedural issue...

The new European Regulations on Medical Devices (EU 2017/745) increasingly impact healthcare and contribute to an industry-wide uncertainty on compliance.

This ruling confirms the alignment of the classification of contraception apps between Swiss and European authorities.

Switzerland is moving ahead with the implementation of the Cost Containment Package 2: On 18 February 2026, the Federal Council opened the consultation on a third set of significant revisions...

Swiss competition law is primarily governed by the Federal Law on Cartels and other Restraints of Competition (LCart).2 The LCart is primarily enforced by the Competition Commission...

Over the past two decades, the health sector has undergone significant technological developments. The ubiquity of digital devices in our daily lives, combined with the ongoing democratization of developments in artificial intelligence (AI), has opened the door to new possibilities.

Am 3. September 2025 hat der Bundesrat die Botschaft zur Teilrevision des HMG zuhanden des Parlaments verabschiedet.

On 3 September 2025, the Federal Council published the dispatch regarding the partial revision of the Therapeutic Products Act (TPA) to be submitted to Parliament.

The current M&A market environment is characterised by non-traditional playbooks and non-linear timelines. In order to reduce execution risks and keep valuation discipline in M&A transactions...

With our unique focus on the Life Sciences and Healthcare sectors, we've stayed at the forefront of current trends and developments in these industries.

In den letzten zwei Jahrzehnten hat der Gesundheits- sektor bedeutsame technologische Entwicklungen durchlaufen.

Since 2001, Switzerland has regulated medical devices in the same way as the EU. The former EU Directives on classical medical devices (93/42/EEC), ...

Switzerland has had to constantly adapt its legislation in this area to align with the heightened standards imposed by the EU.